Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition

Maniar, R., Gallitano, S. M., Husain, S., Moazami, G., Weiss, M. J., & Shu, C. A. (2023). Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition. Journal of the National Comprehensive Cancer Network, 21(3), 232–234. https://doi.org/10.6004/jnccn.2022.7084
Authors:
Rohan Maniar
Stephanie M. Gallitano
Sameera Husain
Golnaz Moazami
Michael J. Weiss
Catherine A. Shu
Affiliated Authors:
Rohan Maniar
Stephanie M. Gallitano
Sameera Husain
Golnaz Moazami
Michael J. Weiss
Catherine A. Shu
Columbia Affiliation:
Subjects:
Carcinoma, Non-Small-Cell Lung (MeSH)
Lung Neoplasms (MeSH)
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Neutrophilic Dermatoses and Inflammatory Bowel Diseases (OpenAlex Topic)
Mammalian MAP Kinase Signaling Pathways (OpenAlex Topic)
Author Keywords:
braf mutation
dabrafenib
retinopathy
sweet’s syndrome
trametinib
elink
Publication Type:
Article
Unique ID:
10.6004/jnccn.2022.7084
PMID:
36758579
DOI:
10.6004/jnccn.2022.7084
Journal:
Journal of the National Comprehensive Cancer Network
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View OpenAlex Record
View PubMed Record

Record Created: